232 related articles for article (PubMed ID: 24292730)
1. Antipsychotic formulation and one-year rehospitalization of schizophrenia patients: a population-based cohort study.
Huang SS; Lin CH; Loh el-W; Yang HY; Chan CH; Lan TH
Psychiatr Serv; 2013 Dec; 64(12):1259-62. PubMed ID: 24292730
[TBL] [Abstract][Full Text] [Related]
2. Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge.
Marcus SC; Zummo J; Pettit AR; Stoddard J; Doshi JA
J Manag Care Spec Pharm; 2015 Sep; 21(9):754-68. PubMed ID: 26308223
[TBL] [Abstract][Full Text] [Related]
3. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
4. Risperidone long-acting injection and 1-year rehospitalization rate of schizophrenia patients: A retrospective cohort study.
Chan HW; Huang CY; Feng WJ; Yen YC
Psychiatry Clin Neurosci; 2015 Aug; 69(8):497-503. PubMed ID: 25781185
[TBL] [Abstract][Full Text] [Related]
5. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia.
Tiihonen J; Haukka J; Taylor M; Haddad PM; Patel MX; Korhonen P
Am J Psychiatry; 2011 Jun; 168(6):603-9. PubMed ID: 21362741
[TBL] [Abstract][Full Text] [Related]
6. Initiating long-acting injectable antipsychotics during acute admission for patients with schizophrenia--A 3-year follow-up.
Liu CC; Shan JC; Chiang CL; Hsieh MH; Liu CM; Chien YL; Chen SC; Hwang TJ
J Formos Med Assoc; 2015 Jun; 114(6):539-45. PubMed ID: 26062967
[TBL] [Abstract][Full Text] [Related]
7. A Comparison of Long-Acting Injectable Antipsychotics With Oral Antipsychotics on Time to Rehospitalization Within 1 Year of Discharge in Elderly Patients With Schizophrenia.
Lin CH; Chen FC; Chan HY; Hsu CC
Am J Geriatr Psychiatry; 2020 Jan; 28(1):23-30. PubMed ID: 31481273
[TBL] [Abstract][Full Text] [Related]
8. Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients With Schizophrenia.
Tiihonen J; Mittendorfer-Rutz E; Majak M; Mehtälä J; Hoti F; Jedenius E; Enkusson D; Leval A; Sermon J; Tanskanen A; Taipale H
JAMA Psychiatry; 2017 Jul; 74(7):686-693. PubMed ID: 28593216
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of long-acting injectable risperidone versus oral antipsychotics in the treatment of recent-onset schizophrenia: a case-control study.
Barrio P; Batalla A; Castellví P; Hidalgo D; García M; Ortiz A; Grande I; Pons A; Parellada E
Int Clin Psychopharmacol; 2013 Jul; 28(4):164-70. PubMed ID: 23587986
[TBL] [Abstract][Full Text] [Related]
10. Time to Rehospitalization in Patients With Schizophrenia Receiving Long-Acting Injectable Antipsychotics or Oral Antipsychotics.
Lin CH; Chen FC; Chan HY; Hsu CC
Int J Neuropsychopharmacol; 2019 Sep; 22(9):541-547. PubMed ID: 31260538
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Injectable and Oral Antipsychotics in Relapse Rates in a Pragmatic 30-Month Schizophrenia Relapse Prevention Study.
Buckley PF; Schooler NR; Goff DC; Kopelowicz A; Lauriello J; Manschreck TC; Mendelowitz A; Miller DD; Wilson DR; Ames D; Bustillo JR; Kane JM; Looney SW
Psychiatr Serv; 2016 Dec; 67(12):1370-1372. PubMed ID: 27476806
[TBL] [Abstract][Full Text] [Related]
12. Long-acting injectables and risk for rehospitalization among patients with schizophrenia in the home care program in Taiwan.
Ju PC; Chou FH; Lai TJ; Chuang PY; Lin YJ; Yang CW; Tang CH
J Clin Psychopharmacol; 2014 Feb; 34(1):23-9. PubMed ID: 24145217
[TBL] [Abstract][Full Text] [Related]
13. Concurrent Oral Antipsychotic Drug Use Among Schizophrenia Patients Initiated on Long-Acting Injectable Antipsychotics Post-Hospital Discharge.
Doshi JA; Pettit AR; Stoddard JJ; Zummo J; Marcus SC
J Clin Psychopharmacol; 2015 Aug; 35(4):442-6. PubMed ID: 26075492
[TBL] [Abstract][Full Text] [Related]
14. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
[TBL] [Abstract][Full Text] [Related]
15. Hospital Readmission Rates Among Patients With Schizophrenia Treated With Long-Acting Injectables or Oral Antipsychotics.
MacEwan JP; Kamat SA; Duffy RA; Seabury S; Chou JW; Legacy SN; Hartry A; Eramo A; Karson C
Psychiatr Serv; 2016 Nov; 67(11):1183-1188. PubMed ID: 27417897
[TBL] [Abstract][Full Text] [Related]
16. Review of treatments that can ameliorate nonadherence in patients with schizophrenia.
Kane JM
J Clin Psychiatry; 2006; 67 Suppl 5():9-14. PubMed ID: 16822091
[TBL] [Abstract][Full Text] [Related]
17. Do Long-Acting Injectable Antipsychotics Prevent or Delay Hospital Readmission?
Maestri TJ; Mican LM; Rozea H; Barner JC
Psychopharmacol Bull; 2018 Mar; 48(3):8-15. PubMed ID: 29713100
[TBL] [Abstract][Full Text] [Related]
18. Relapse and rehospitalization: comparing oral and depot antipsychotics.
Schooler NR
J Clin Psychiatry; 2003; 64 Suppl 16():14-7. PubMed ID: 14680414
[TBL] [Abstract][Full Text] [Related]
19. Continuation of schizophrenia treatment with three long-acting injectable antipsychotics in South Korea: A nationwide population-based study.
Joo SW; Shon SH; Choi G; Koh M; Cho SW; Lee J
Eur Neuropsychopharmacol; 2019 Sep; 29(9):1051-1060. PubMed ID: 31362852
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
